Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 268-274

  Baumeister, Philipp ^a   Reiter, Maximilian ^a   Schwenk Zieger, Sabina ^a   Harréus, Ulrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemoresistance to cisplatin; Head and neck squamous cell carcinoma; Transforming growth factor stimulation

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; HUMAN; HUMAN TISSUE; OROPHARYNX; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TISSUE CULTURE; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MUCOUS MEMBRANE; OROPHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE CULTURE TECHNIQUES; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 77955214015     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319902     Document Type: Article

References (40)

1. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor numberdependent manner. Clin Cancer Res 1997; 11: 2099-2106.
2. Kalyankrishna S, Grandis JR: Epidermal growth factor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672.
3. Lee JW, Soung YH, Kim SY: Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879-2883.
4. Nishio K, Arao T, Kato T: EGFR mutation in various tissue. Cancer Chemother Pharmacol 2006; 58:S39-S41.
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
6. Bernier J: Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006; 6: 1539-1552.
7. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, Peters GE, Carroll WR, Waksal HW: Enhanced apoptosis with combination C225/ radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18: 47S-53S.
8. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56: 3666-3669.
9. Huang SM, Li J, Harari PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002; 1: 507-514.
10. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5: 257-262.
11. Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J: Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett 2009; 283: 135-142.
12. Danielsen AJ, Maihle NJ: The EGF/ErbB receptor family and apoptosis. Growth Factors 2002; 20: 1-15.
13. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA: Roles of the Raf/MEK/ ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284.
14. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S: Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305-313.
15. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2009; 359: 1116-1127.
16. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H: Cetuximab induce antibody- dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-787.
17. Hasegawa Y, Goto M, Hanai N, Ijichi K, Terada A, Hyodo I, Ogawa T, Fukushima M: Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology 2007; 73: 104-111.
18. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
19. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-1292.
20. Kleinsasser NH, Juchhoff J, Wallner BC, Bergner A, Harréus UA, Gamarra F, Bührlen M, Huber RM, Rettenmeier AW: The use of mini-organ cultures of human upper aerodigestive tract epithelia in ecogenotoxicology. Mutat Res 2004; 561: 63-73.
21. Teissier E, Fennrich S, Strazielle N, Daval JL, Ray D, Schlosshauer B, Ghersi-Egea JF: Drug metabolism in in vitro organotypic and cellular models of mammalian central nervous system: activities of membrane-bound epoxide hydrolase and NADPH-cytochrome P-450 (c) reductase. Neurotoxicology 1998; 19: 347-355.
22. Schmeichel KL, Bissell MJ: Modeling tissuespecific signaling and organ function in three dimensions. J Cell Sci 2003; 116: 2377-2388.
23. Halliwell B, Whiteman M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004; 142: 231-255.
24. Blasiak J, Kowalik J, Małecka-Panas E, Drzewoski J, Wojewódzka M: DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Teratog Carcinog Mutagen 2000; 20: 119-131.
25. Harréus U, Schmezer P, Kuchenmeister F, Maier H: Genotoxic effect of human mucous membrane biopsies of the upper aerodigestive tract. Laryngorhinootologie 1999; 78: 176-181.
26. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
27. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-1542.
28. Reedijk J: Why does cisplatin reach guanine- N7 with competing S-donor ligands available in the cell? Chem Rev 1999; 99: 2499-2510.
29. Yellina SA, Davidson BJ, Pinto JT, Sacks PG, Qiao C, Schantz SP: Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 1994; 85: 223-232.
30. Rotte A, Garmann D, Buss I, Jaehde U: Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian caner cells. Chemotherapy 2010; 56: 1-8.
31. O'Driscoll L, Clynes M: Molecular markers of multiple drug resistance in breast cancer. Chemotherapy 2006; 52: 125-129.
32. Stavrovskaya AA, Stromskaya TP: Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry 2008; 73: 592-604.
33. Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-7552.
34. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996; 56: 4124-4129.
35. Ishikawa T, Ali-Osman F: Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-20125.
36. Baumeister P, Reiter M, Schwenk-Zieger S, Welz C, Harréus U: Transforming growth factor-alpha reduces carcinogen-induced DNA-damage in mini-organ cultures from head and neck cancer patients. Mutat Res 2009; 677: 42-45.
37. Garcia R, Franklin RA, McCubrey JA: EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006; 5: 2820-2826.
38. Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grénman R, Werner JA: Cisplatin resistance of the HNSCC cell line UTSCC- 26A can be overcome by stimulation of the EGF-receptor. Anticancer Res 2009; 29: 1181-1188.
39. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A, Werner JA: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux®) results in a paradox phosphorylation of tyrosine 1,173 in the receptor. FEBS Lett 2006; 580: 4793-4800.
40. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 2005; 5: 341-354.